Blog Flex Databases
October 12, 2021
Using Artificial Intelligence in Pharmacovigilance
As we briefly discussed in the previous chapter, Artificial Intelligence (AI) is used to simulate the processes of a human brain with the help of computer systems.
Learn more→
April 27, 2021
Exom Group implements Flex Databases CTMS and Pharmacovigilance
At the very end of winter, Flex Databases signed a contract for CTMS and Pharmacovigilance module implementation with Italian Human & Digital CRO Exom Group. We’ve asked Luigi Visani, MD, President & CEO at Exom Group a couple of questions about the upcoming partnership:
Learn more→
November 27, 2020
How to move to post-Brexit pharmacovigilance effortlessly and efficiently
In 2021 the United Kingdom is moving to its post-Brexit life with new processes, procedures, and laws everywhere, including clinical trials and pharmacovigilance. This piece we dedicate to a simple question – how to move to post-Brexit pharmacovigilance effortlessly and efficiently.
Learn more→
July 27, 2020
Tranquil Clinical Research selects Flex Databases CTMS and Pharmacovigilance
United States-based Tranquil Clinical Research recently signed Flex Databases as a software provider for Clinical Trial Management System and Pharmacovigilance management solution.
Learn more→
December 13, 2019
Signal management is now free
Flex Databases Signal Management tool in Pharmacovigilance module utilizes modern qualitative and quantitative (statistical, machine learning, neural network) methods to detect signals more precisely. And, from now on, it is provided for free for all Pharmacovigilance module buyers.
Learn more→
[image]
July 16, 2019
Gateway to China
The drug regulatory authority of China – National Medical Product Administration (NMPA, formerly CFDA) has recently implemented a possibility to report Adverse Drug Reactions (ADR) through an XML-file submission. Flex Databases Pharmacovigilance system users are already able to do so.
Learn more→
Join Our Newsletter
Want to get the latest news on clinical trials? Get our insights straight to your inbox.




